{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-280173","form_type":"8-K","ticker":"EQ","cik":"0001746466","company_name":"Equillium, Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.327879+00:00","generated_at":"2026-05-16T20:28:33.839140+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Equillium reports Q3 net loss of $4.2M; announces $50M financing and EQ504 Phase 1 plan for mid-2026","bullets":["Q3 2025 revenue $0 vs $12.2M in prior year; net loss $4.2M ($0.06 per share) vs $7,000 loss in Q3 2024.","Closed private placement of up to $50M; initial $30M tranche funded by ADAR1, Janus Henderson, Adage, Coastlands, Woodline.","Cash and investments $33.1M at Sep 30, 2025 vs $22.6M at Dec 31, 2024; expected runway through 2027.","EQ504 (AhR modulator) for ulcerative colitis Phase 1 study expected to initiate mid-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-280173","json":"https://secwatch.observer/filing/0001193125-25-280173.json","markdown":"https://secwatch.observer/filing/0001193125-25-280173.md","text":"https://secwatch.observer/filing/0001193125-25-280173.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746466/000119312525280173/0001193125-25-280173-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746466/000119312525280173/eq-20251113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:28:33.839140+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}